Literature DB >> 6234282

Treatment of acute urinary infection by norfloxacin or nalidixic acid/citrate: a multi-centre comparative study.

D S Reeves, R W Lacey, R V Mummery, M Mahendra, A J Bint, S W Newsom.   

Abstract

The efficacy, tolerability and side effects of a 3-day treatment for acute urinary infection in general practice with norfloxacin (400 mg 12 hourly) or nalidixic acid/citrate (1 sachet 8 hourly) were compared in a randomized study. Patient groups had similar demography, symptomatology and initial infecting bacteria. Of the evaluable 55 patients in each treatment group with initial bacteriuria, 53 (96%) had no bacteriuria at immediate follow-up after treatment with norfloxacin and 45 (82%) with nalidixic acid/citrate. The corresponding rates at late follow-up were 40/45 (89%) and 29/43 (67%) (P less than 0.05). Among the bacteriuric patients a significantly greater proportion were recorded as having cured and improved symptoms. The tolerability of norfloxacin seemed to be better than that of nalidixic acid/citrate.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6234282     DOI: 10.1093/jac/13.suppl_b.99

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.

Authors:  Matthew G Blango; Matthew A Mulvey
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

Review 2.  [Central nervous system side effects of different antibacterial substances].

Authors:  G Stoppe; E Rüther
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 3.  Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

4.  Clinical uses of nalidixic acid analogues: the fluoroquinolones.

Authors:  N Høiby
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

Review 5.  Quinolone antibacterial agents for the treatment of genitourinary tract infections.

Authors:  T J Babinchak; R J Fass
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

Review 6.  The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

Authors:  D C Hooper; J S Wolfson
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

7.  Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.

Authors:  G Del Río; F Dalet; L Aguilar; J Caffaratti; R Dal-Ré
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 8.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

Review 9.  Urinary alkalisation for symptomatic uncomplicated urinary tract infection in women.

Authors:  Dermot B O'Kane; Sameer K Dave; Neel Gore; Farhaan Patel; Tammy C Hoffmann; Jeanne L Trill; Chris B Del Mar
Journal:  Cochrane Database Syst Rev       Date:  2016-04-19

10.  Treating acute urinary tract infections. An RCT of 3-day versus 7-day norfloxacin.

Authors:  T A Trienekens; N H London; A W Houben; R A De Jong; E E Stobberingh
Journal:  Can Fam Physician       Date:  1993-03       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.